vimarsana.com

Latest Breaking News On - Ramesh narayanan - Page 1 : vimarsana.com

Choose strategy for digital ID wallet integration, governance frameworks carefully

Enrollment Continues in Study Evaluating ONCT-534 For Advanced Prostate Cancer

Patients continue to be enrolled in a study evaluating the dual-action androgen receptor inhibitor ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPIs).

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.